Overview

HL2351 CAPS Phase II Study

Status:
Terminated

Trial end date:
2019-01-01

Target enrollment:

Participant gender:

Summary

This is an open label, single arm trial to evaluate the efficacy, safety, and pharmacokinetics of HL2351 in patients with cryopyrin associated periodic syndromes (CAPS).

Phase:

Phase 2

Details

Lead Sponsor:

Handok Inc.
Handok Pharmaceuticals Co., Ltd.